STAAR Surgical Company (STAA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

STAAR Surgical Company (STAA) Healthcare & Pipeline Overview

STAAR Surgical Company specializes in implantable ophthalmic lenses, primarily the Visian ICL, offering a premium alternative to laser vision correction. With a focus on expanding its global market presence and technological advancements in lens design, STAAR Surgical addresses the growing demand for refractive vision correction within the medical instruments and supplies sector.

What Is the Investment Thesis for STAA?

The company's focus on expanding its global market presence, particularly in high-growth markets like China and India, is expected to fuel revenue growth. STAAR Surgical's high gross margin of 75.6% indicates strong pricing power and efficient operations. However, the company's negative profit margin of -33.6% raises concerns about profitability and expense management. Key catalysts include continued product innovation and regulatory approvals in new markets. Investors should monitor the company's ability to improve profitability and manage its operating expenses effectively.

Based on FMP financials and quantitative analysis

STAA Key Highlights

Market capitalization of $1.17B reflects investor valuation of STAAR Surgical's growth potential in the ophthalmic market.

• Gross margin of 75.6% demonstrates strong pricing power and efficient manufacturing processes.
• Negative profit margin of -33.6% indicates challenges in achieving profitability despite high revenue.
• Beta of 1.04 suggests the stock's volatility is similar to the overall market.
• No dividend is currently offered, indicating a focus on reinvesting earnings for growth.

Who Are STAA's Competitors?

STAA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are STAA's Key Strengths?

Proprietary Visian ICL technology

• High gross margin
• Established distribution network
• Strong brand reputation

What Are STAA's Weaknesses?

Negative profit margin

• High dependence on Visian ICL sales
• Limited product diversification
• Relatively small market capitalization

What Could Drive STAA Stock Higher?

Regulatory approvals for Visian ICL in new markets, expanding the addressable patient population.

• Increasing adoption of Visian ICL by ophthalmic surgeons due to its clinical benefits.
• Expansion of direct sales force in key markets to drive revenue growth.
• Launch of new Visian ICL product iterations with enhanced features and capabilities.

What Are the Key Risks for STAA?

Rich valuation — a P/E of 292.75 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Competition from established laser vision correction technologies and other intraocular lenses.
• Economic downturns affecting consumer spending on elective medical procedures.
• Regulatory hurdles and delays in obtaining approvals for new products and markets.
• Product liability claims and recalls affecting brand reputation and financial performance.

What Are the Growth Opportunities for STAA?

• Expansion in China: The Chinese market represents a significant growth opportunity for STAAR Surgical due to the high prevalence of myopia and increasing adoption of advanced vision correction technologies. By expanding its sales and marketing efforts in China and obtaining regulatory approvals for new products, STAAR Surgical can capitalize on this large and growing market. The market size for vision correction in China is estimated to be in the billions of dollars, offering substantial revenue potential.
• Product Innovation: Continued investment in research and development to enhance the Visian ICL platform and develop new ophthalmic solutions is crucial for STAAR Surgical's long-term growth. This includes developing lenses with improved optical performance, expanding the range of treatable conditions, and creating more efficient delivery systems. Successful product innovation will strengthen STAAR Surgical's competitive advantage and drive adoption by ophthalmic surgeons.
• Geographic Expansion: Expanding into new geographic markets, particularly in developing countries with growing middle classes and increasing awareness of vision correction options, presents a significant growth opportunity. This includes establishing distribution networks, obtaining regulatory approvals, and conducting marketing campaigns to educate potential customers about the benefits of the Visian ICL. Key target markets include India, Southeast Asia, and Latin America.
• Strategic Partnerships: Forming strategic partnerships with ophthalmic clinics, hospitals, and vision centers can help STAAR Surgical expand its reach and increase adoption of its products. These partnerships can provide access to established patient networks and enhance the company's credibility with ophthalmic surgeons. Strategic alliances can also facilitate the development and commercialization of new ophthalmic technologies.
• Direct-to-Consumer Marketing: Implementing direct-to-consumer marketing campaigns to raise awareness of the Visian ICL and educate potential patients about its benefits can drive demand and increase sales. This includes utilizing online advertising, social media, and patient education events to reach a wider audience. Effective direct-to-consumer marketing can help STAAR Surgical differentiate itself from competitors and establish a strong brand presence.

What Are STAA's Competitive Advantages?

• Proprietary Visian ICL technology offers a unique alternative to laser vision correction.
• Strong brand reputation among ophthalmic surgeons and patients.
• Extensive distribution network in key markets worldwide.
• High switching costs for surgeons trained on the Visian ICL system.

What Does STAA Do?

STAAR Surgical Company, founded in 1982 and headquartered in Lake Forest, California, is a leading developer, manufacturer, and marketer of implantable lenses and delivery systems for the eye. The company's core product is the Visian Implantable Collamer Lens (ICL) family, designed to correct a range of visual disorders, including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia. The ICL offers a unique alternative to traditional laser vision correction procedures, providing patients with excellent vision quality and a reversible treatment option. STAAR Surgical also offers preloaded silicone cataract intraocular lenses and injector systems used in cataract surgery. The company distributes its products globally, utilizing a direct sales force in key markets such as the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through a network of representatives and independent distributors in other regions, including China, Korea, India, France, Benelux, and Italy. STAAR Surgical's focus on innovation and expanding its product portfolio positions it as a significant player in the ophthalmic medical device market.

What Products and Services Does STAA Offer?

• Designs and develops implantable lenses for the eye.
• Manufactures and markets the Visian Implantable Collamer Lens (ICL) family.
• Provides solutions for correcting myopia, hyperopia, astigmatism, and presbyopia.
• Offers preloaded silicone cataract intraocular lenses and injector systems.
• Sells injector parts and related instruments and devices.
• Markets products to ophthalmic surgeons, vision centers, and hospitals.

How Does STAA Make Money?

• Develops and manufactures implantable lenses for vision correction.
• Sells lenses and delivery systems directly to healthcare providers and through distributors.
• Generates revenue from the sale of Visian ICLs and cataract lenses.
• Provides ongoing support and training to ophthalmic surgeons.

What Industry Does STAA Operate In?

STAAR Surgical operates in the medical instruments and supplies industry, which is characterized by technological innovation and increasing demand for advanced medical devices. The global market for ophthalmic devices is expected to grow, driven by an aging population and rising prevalence of vision disorders. STAAR Surgical competes with companies offering laser vision correction technologies and other intraocular lenses. The company's Visian ICL provides a differentiated solution with its reversibility and excellent vision quality, positioning it to capture a significant share of the refractive surgery market.

Who Are STAA's Key Customers?

• Ophthalmic surgeons
• Vision and surgical centers
• Government facilities
• Distributors

STAAR Surgical Company Financial Trajectory

STAAR Surgical Company (STAA) reported $93.5M in revenue for Q2 FY2026, reflecting 0.0% growth compared to the prior quarter. The company recorded net income of $8.1M, with diluted EPS of $0.16. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, STAA averaged $0.02 in diluted EPS.

Company Profile

STAAR Surgical Company operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Lake Forest, US. The company is led by CEO Warren Foust. STAA has traded publicly since 1992.

How STAAR Surgical Company Is Valued

STAAR Surgical Company carries a market capitalization of $1.17B, placing it in the small-cap category. Analyst price targets span from $27.00 to $40.00, with a consensus of $31.50. At the current price of $23.42, that implies approximately 35% upside potential. Relative to its peer group, STAA's quantitative score of 39/100 is below the peer average of 64/100.

Return on equity for STAAR Surgical Company stands at 1.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.8%, showing how much profit it generates from its asset base. STAA trades at a trailing price-to-earnings ratio of 292.75, above the Healthcare sector average of ~21.50x. Its free cash flow yield is -0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.3%, the inverse of the P/E and a quick read on earnings relative to price.

STAAR Surgical Company's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 7.54 places it in the safe zone, indicating low near-term bankruptcy risk.

STAAR Surgical Company has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 242.1% below estimates on average.

Wall Street analysts project STAAR Surgical Company revenue of about $334.6M for fiscal 2027, with EPS near $0.28. The estimate reflects 8 contributing analysts.

Over the past six months, STAAR Surgical Company insiders filed 30 SEC Form 4 transactions — 9 sales and 21 purchases. On net that is roughly 433K shares acquired (about $8.9M) — insiders putting money in tends to read as conviction.

STAA Financials

STAA Latest News

STAA Analyst Consensus

STAA MoonshotScore

STAAR Surgical Company Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources